Wet AMD Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2036 | DelveInsight

DelveInsight's 'Wet AMD Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Wet AMD, historical and forecasted epidemiology, as well as the Wet AMD market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Wet AMD Treatment Market Report @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Wet AMD Market Report
• In April 2026, Regeneron Pharmaceuticals, Inc. announced that the US FDA approved extending dosing intervals for EYLEA HD (aflibercept) up to every 20 weeks in wet AMD and Diabetic Macular Edema (DME) patients after one year of response, supported by 2-year data from the PULSAR and PHOTON trials showing sustained efficacy and safety.
• According to DelveInsight's estimates, the total prevalent cases of Wet AMD in the 7MM were approximately 3 million in 2025.
• The age-specific distribution of Wet AMD in the US demonstrates a substantial increase with advancing age, with the highest prevalence observed among individuals aged ≥85 years, highlighting the growing epidemiological burden in the elderly population and the need for timely diagnosis and management to reduce vision-related complication.
• In 2025, early and intermediate AMD accounted for the majority of stage-specific AMD cases, whereas late-stage AMD (nAMD and geographic atrophy) represented a significantly smaller proportion, highlighting that most patients are diagnosed before progression to advanced disease stages, in Japan.
• The leading Wet AMD Companies include Regeneron Pharmaceuticals, Bayer, Genentech, Kodiak Sciences, AbbVie, Regenxbio, Caregen, NexThera, and others.
• Promising Wet AMD Therapies include Aflibercept (EYLEA HD), Ranibizumab (LUCENTIS), Faricimab (VABYSMO), KSI-501, RGX-314, CG-P5 peptide, NT-101, and others.

Get a Free sample for the Wet AMD Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Wet AMD Overview
WET AMD is an advanced form of Age-related Macular Degeneration, occurring when abnormal blood vessels grow beneath the retina and leak fluid or blood, leading to rapid and severe vision loss. It can progress quickly, with symptoms such as blurred or distorted central vision, dark spots, and difficulty recognizing faces, especially in later stages. Wet AMD is mainly caused by abnormal vascular growth driven by factors like aging and oxidative stress. Diagnosis is based on eye examinations and imaging tests such as Optical Coherence Tomography (OCT) and fluorescein angiography.

Wet AMD Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of AMD
• Stage-specific Cases of AMD
• Total Prevalent Cases of Wet AMD
• Total Diagnosed Prevalent Cases of Wet AMD
• Age-specific Cases of Wet AMD
• Total Treated Cases of Wet-AMD

Download the report to understand which factors are driving Wet AMD Epidemiology trends @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Approved Therapies for Wet AMD
• Aflibercept (EYLEA HD): Regeneron Pharmaceuticals/Bayer

Aflibercept (EYLEA HD), jointly developed by Regeneron Pharmaceuticals and Bayer, is an 8 mg high-dose formulation of Aflibercept designed to provide extended durability in retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). By inhibiting Vascular Endothelial Growth Factor (VEGF)-driven abnormal blood vessel growth and leakage, it helps maintain vision while allowing longer dosing intervals of up to 12-16 weeks, reducing treatment burden. Approved by the US FDA in 2023, EYLEA HD represents an advancement over standard anti-VEGF therapies by improving convenience without compromising efficacy. The formulation of EYLEA is protected in Europe by a patent granted by the European Patent Office until June 2027.

• Ranibizumab (LUCENTIS): Genentech

Ranibizumab (Susvimo), developed by Genentech, is a refillable, implantable ocular drug delivery system designed for the treatment of Wet AMD. It utilizes a port delivery system (PDS) surgically implanted into the eye, continuously releasing a customized formulation of ranibizumab, a VEGF inhibitor, over an extended period. This approach maintains therapeutic drug levels in the retina, reducing the need for frequent intravitreal injections typically required with standard anti-VEGF therapies. By enabling refill intervals of up to six months or longer, LUCENTIS improves treatment adherence and reduces patient burden while providing sustained vision outcomes, addressing a significant unmet need in the long-term management of wet AMD.

Wet AMD Pipeline Analysis
• KSI-501: Kodiak Sciences

KSI-501, developed by Kodiak Sciences, is an investigational anti-VEGF antibody biopolymer conjugate being developed for the treatment of Wet AMD. The therapy is based on Kodiak's Antibody Biopolymer Conjugate (ABC) platform, which is designed to enhance durability and prolong retinal drug exposure following intravitreal administration. By enabling sustained VEGF inhibition, KSI-501 aims to reduce injection frequency and lower the overall treatment burden for patients with Wet AMD. Clinical studies have demonstrated encouraging durability, retinal bioavailability, and sustained therapeutic activity, supporting its development as a long-acting retinal vascular disease therapy. Currently, the drug is being evaluated in Phase III clinical trials for Wet AMD.

• ABBV-RGX-314: AbbVie/Regenxbio

RGX-314, developed by AbbVie in collaboration with REGENXBIO, is a gene therapy designed for the treatment of Wet AMD. It utilizes an Adeno-Associated Virus (AAV) vector to deliver a gene encoding a monoclonal antibody fragment that inhibits VEGF, enabling sustained intraocular anti-VEGF protein production. This approach aims to reduce or eliminate the need for frequent intravitreal injections, providing long-term disease control. RGX-314 has demonstrated promising durability and efficacy in clinical studies, with ongoing trials evaluating both subretinal and suprachoroidal delivery methods to improve patient outcomes and treatment convenience. Currently, RGX-314 for Wet AMD via subretinal delivery is being evaluated in Phase III clinical trials, while the suprachoroidal delivery approach is in Phase II development.

Discover more about therapies set to grab Major Wet AMD Market Share @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Wet AMD Companies
Regeneron Pharmaceuticals, Bayer, Genentech, Kodiak Sciences, AbbVie, Regenxbio, Caregen, NexThera, and others.

Wet AMD Market Outlook
The Wet AMD market is undergoing a significant shift from frequent intravitreal anti-VEGF injections toward more durable and innovative therapeutic approaches aimed at reducing treatment burden and improving long-term outcomes. While established therapies such as Aflibercept (EYLEA) and Ranibizumab (LUCENTIS) continue to dominate, recent advancements including high-dose formulations, extended dosing regimens, and sustained delivery systems are reshaping the standard of care. Technologies such as port delivery systems and gene therapies (e.g., LUCENTIS and RGX-314) highlight the shift toward long-acting solutions that maintain efficacy while minimizing injection frequency, thereby enhancing patient adherence and quality of life.

Wet AMD Treatment Landscape
Wet AMD treatments such as Eylea, Lucentis, and Avastin show high uptake, while newer agents like Vabysmo and Eylea HD are gaining traction due to extended dosing intervals and reduced treatment burden. Emerging options, including the Port Delivery System with ranibizumab and gene therapies (NG101), are expected to see gradual uptake as they address frequent injection burden and improve long-term management. With a robust pipeline of emerging therapies, including bispecific antibodies, ocular gene therapies, and novel peptides targeting angiogenesis and inflammation, the treatment landscape is rapidly evolving. These innovations aim to address key unmet needs such as durability, suboptimal responders to anti-VEGF therapy, and real-world treatment burden. The United States continues to represent the largest market, driven by high disease prevalence, strong reimbursement frameworks, and rapid uptake of advanced therapies, followed by EU4 and the United Kingdom and Japan.

To know more about Wet AMD Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Wet AMD Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Wet AMD Companies- Regeneron Pharmaceuticals, Bayer, Genentech, Kodiak Sciences, AbbVie, Regenxbio, Caregen, NexThera, and others.
• Wet AMD Therapies- Aflibercept (EYLEA HD), Ranibizumab (LUCENTIS), Faricimab (VABYSMO), KSI-501, RGX-314, CG-P5 peptide, NT-101, and others.
• Wet AMD Therapeutic Assessment- Wet AMD current marketed and emerging therapies
• Wet AMD Market Dynamics: Wet AMD market drivers and market barriers
• Wet AMD Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Wet AMD Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Explore more information about the Wet AMD Therapeutics Market Report @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Wet AMD
4. Key Events of Wet AMD
5. Epidemiology and Market Methodology of Wet AMD
6. Wet AMD Market Overview at a Glance
7. Disease Background And Overview of Wet AMD
8. Epidemiology and Patient Population of Wet AMD
9. Patient Journey of Wet AMD
10. Marketed Therapies of Wet AMD
11. Emerging Therapies of Wet AMD
12. Wet AMD: 7MM Analysis
13. Unmet Needs of Wet AMD
14. SWOT Analysis of Wet AMD
15. KOL Views of Wet AMD
16. Market Access and Reimbursement of Wet AMD
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.